๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Advanced bladder cancer...Where are we now and where are we going?

โœ Scribed by Michael F. Sarosdy; Stefan Machtens

Publisher
Springer-Verlag
Year
2002
Tongue
English
Weight
42 KB
Volume
20
Category
Article
ISSN
0724-4983

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Where we are, and where we are going
Where we are, and where we are going
โœ Alexander T. Shulgin ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› Elsevier ๐ŸŒ English โš– 355 KB

This presentation is a review of the present state of the war on drugs in the United States today, from the legal and judicial viewpoints,

Understanding diabetic teratogenesis: Wh
Understanding diabetic teratogenesis: Where are we now and where are we going?
โœ Sheller Zabihi; Mary R. Loeken ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 154 KB ๐Ÿ‘ 2 views

## Abstract Maternal pregestational diabetes (type 1 or type 2) poses an increased risk for a broad spectrum of birth defects. To our knowledge, this problem first came to the attention of the Teratology Society at the 14th Annual Meeting in Vancouver, B.C. in 1974, with a presentation by Lewis Hol

Dopamine D1 receptor ligands: Where are
Dopamine D1 receptor ligands: Where are we now and where are we going
โœ Jing Zhang; Bing Xiong; Xuechu Zhen; Ao Zhang ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 285 KB

The dopamine (DA) D(1) receptor is the most highly expressed DA receptor subtype among the DA receptor family. Although the first DA D(1) receptor selective ligand SCH-23390 (1) was introduced more than two decades ago, clinically useful D(1) receptor selective ligands are rare. A renewed interest w